Clinical Trial Update: A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating second-line treatment with Apatinib after TACE in advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN